PE20110420A1 - Nuevos derivados de 2-amidotiadiazol - Google Patents

Nuevos derivados de 2-amidotiadiazol

Info

Publication number
PE20110420A1
PE20110420A1 PE2011000839A PE2011000839A PE20110420A1 PE 20110420 A1 PE20110420 A1 PE 20110420A1 PE 2011000839 A PE2011000839 A PE 2011000839A PE 2011000839 A PE2011000839 A PE 2011000839A PE 20110420 A1 PE20110420 A1 PE 20110420A1
Authority
PE
Peru
Prior art keywords
alkyl
thadiazol
aminosulfonil
phenyl
amidotiadiazole
Prior art date
Application number
PE2011000839A
Other languages
English (en)
Inventor
Poveda Pedro Manuel Grima
Izquierdo Nuria Aguilar
Marta Mir Cepeda
Martinez Manuel Lopez
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of PE20110420A1 publication Critical patent/PE20110420A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 2-AMIDOTIADIAZOL DE FORMULA (I) DONDE R1 ES HETEROARILO BICICLICO DE 8 A 10 MIEMBROS QUE CONTIENE N, PIRIDILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, OH, ALQUILO(C1-C4), ENTRE OTROS, PIRIDINONA OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C4) O HALOALQUILO(C1-C4), ENTRE OTROS; R2 ES ARILO(C5-C10) MONOCICLICO O BICICLICO, HETEROARILO DE 5 A 10 MIEMBROS MONOCICLICO O BICICLICO, O DIHIDROBENZODIOXINA; R3 ES ALQUILO(C1-C6), CICLOALQUIL(C3-C6)-ALQUILO(C1-C4), ALCOXI(C1-C4)-ALQUILO(C1-C4), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{5-[4-(AMINOSULFONIL)FENIL]-1,3,4-TIADIAZOL-2-IL}-N-BUTIL-3-METOXI-BENZAMIDA; N-{5-[4-(AMINOSULFONIL)FENIL]-1,3,4-TIADIAZOL-2-IL}-N-BUTIL-2-NAFTAMIDA; N-{5-[4-(AMINOSULFONIL)FENIL]-1,3,4-TIADIAZOL-2-IL}-N-BUTILBIFENIL-4-CARBOXAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS OTRO COMPUESTO COMO: BETASERON, AVONEX, ACETATO DE GLATIRAMER, MITOXANTRONA, NATALIZUMAB, ENTRE OTROS. DICHOS COMPUESTOS SON AGONISTAS DE LOS RECEPTORES 1-FOSFATO DE ESFINGOSINA (S1P1) SIENDO UTILES EN EL TRATAMIENTO DE ESCLEROSIS MULTIPLE, RECHAZO DE TRASPLANTES, LUPUS ERITEMATOSO SISTEMICO, ASMA
PE2011000839A 2008-10-14 2009-10-13 Nuevos derivados de 2-amidotiadiazol PE20110420A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08382042A EP2177521A1 (en) 2008-10-14 2008-10-14 New 2-Amidothiadiazole Derivatives

Publications (1)

Publication Number Publication Date
PE20110420A1 true PE20110420A1 (es) 2011-07-01

Family

ID=40386238

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000839A PE20110420A1 (es) 2008-10-14 2009-10-13 Nuevos derivados de 2-amidotiadiazol

Country Status (20)

Country Link
US (1) US20110200557A1 (es)
EP (2) EP2177521A1 (es)
JP (1) JP2012505260A (es)
KR (1) KR20110067034A (es)
CN (1) CN102186847A (es)
AR (1) AR073821A1 (es)
AU (1) AU2009304274A1 (es)
BR (1) BRPI0914371A2 (es)
CA (1) CA2740614A1 (es)
CL (1) CL2011000795A1 (es)
CO (1) CO6321168A2 (es)
EA (1) EA201100612A1 (es)
EC (1) ECSP11010842A (es)
IL (1) IL211290A0 (es)
MX (1) MX2011003692A (es)
PE (1) PE20110420A1 (es)
TW (1) TW201018679A (es)
UY (1) UY32167A (es)
WO (1) WO2010043377A1 (es)
ZA (1) ZA201101236B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103188936B (zh) * 2010-08-31 2016-04-20 陶氏益农公司 杀虫组合物
RU2448961C1 (ru) * 2011-02-03 2012-04-27 Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") Фармацевтическая композиция, обладающая противовоспалительной, бронхолитической, противотуберкулезной активностями
MX350121B (es) 2011-03-18 2017-08-28 Bayer Ip Gmbh Derivados de n-(3-carbamoilfenil)-1h-pirazol-5-carboxamida y el uso de los mismos para el control de plagas de animales.
CN102276554B (zh) * 2011-06-28 2013-10-30 四川大学 4-（（2-氨基-5-巯基-1,3,4-噻二唑）-甲基）-苯甲酰胺衍生物及其制备方法和用途
FR2988000A1 (fr) * 2012-03-16 2013-09-20 Thomas Wandji Composition pharmaceutique active dans la therapie des affections virales humaines et animales
EP2914591B1 (en) * 2012-11-03 2017-10-11 Boehringer Ingelheim International GmbH Inhibitors of cytomegalovirus
WO2014070979A1 (en) * 2012-11-03 2014-05-08 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
CN106397149B (zh) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 五氟苯甲醛的制备方法
EP3619196B1 (de) 2017-05-04 2022-03-30 Bayer CropScience Aktiengesellschaft 2-{[2-(phenyloxymethyl)pyridin-5-yl]oxy}-ethanamin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel z.b. für den pflanzenschutz
RU2672887C1 (ru) * 2018-03-13 2018-11-20 Акционерное общество "Всесоюзный научный центр по безопасности биологически активных веществ (АО "ВНЦ БАВ") N-(5-Этил-1,3,4-тиадиазол-2-ил)-2-пропилпентанамид, обладающий противоэпилептической и обезболивающей активностями
CN114149297A (zh) * 2021-12-07 2022-03-08 北京中医药大学 一种微波辅助的选择性芳基甲醛的绿色合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000943A1 (en) 1992-06-23 1994-01-06 Motorola, Inc. Multi-modulation scheme compatible radio
HU220227B (hu) 1995-06-21 2001-11-28 Asta Medica A.G. Gyógyszerporos patron integrált adagolószerkezettel és inhalálókészülék poralakú gyógyszerekhez
CN1516695A (zh) * 2001-04-19 2004-07-28 用作抗病毒剂的芳基磺酰胺类化合物
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
KR20120125398A (ko) 2002-05-16 2012-11-14 노파르티스 아게 암에서 ｅｄｇ 수용체 결합제의 용도
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
EP1484057A1 (en) 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
EP1663188B1 (en) 2003-09-12 2016-08-10 Newron Sweden AB Treatment of disorders of the nervous system
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
RU2008134702A (ru) 2006-01-27 2010-03-10 Юниверсити Оф Вирждиния Пэтент Фаундейшн (Us) Способ лечения невропатической боли
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2392320A1 (en) 2006-08-17 2011-12-07 University Of Chicago Treatment of inflammatory diseases
CA2661315C (en) * 2006-09-08 2015-11-24 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
WO2008091967A1 (en) * 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
GB0704394D0 (en) * 2007-03-07 2007-04-11 Senexis Ltd Compounds

Also Published As

Publication number Publication date
MX2011003692A (es) 2011-04-27
UY32167A (es) 2010-01-05
CN102186847A (zh) 2011-09-14
EP2177521A1 (en) 2010-04-21
BRPI0914371A2 (pt) 2019-09-24
JP2012505260A (ja) 2012-03-01
CL2011000795A1 (es) 2011-08-19
AR073821A1 (es) 2010-12-01
KR20110067034A (ko) 2011-06-20
US20110200557A1 (en) 2011-08-18
ZA201101236B (en) 2011-09-28
CA2740614A1 (en) 2010-04-22
ECSP11010842A (es) 2011-03-31
EA201100612A1 (ru) 2011-12-30
CO6321168A2 (es) 2011-09-20
TW201018679A (en) 2010-05-16
WO2010043377A1 (en) 2010-04-22
IL211290A0 (en) 2011-04-28
AU2009304274A1 (en) 2010-04-22
EP2334670A1 (en) 2011-06-22

Similar Documents

Publication Publication Date Title
PE20110420A1 (es) Nuevos derivados de 2-amidotiadiazol
PE20130155A1 (es) Derivados de ariletinilo
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
ES2590504T3 (es) N-ciclilamidas como nematicidas
PE20130039A1 (es) Pirazoles fungicidas
BR112013009935B8 (pt) Compostos
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
PE20120081A1 (es) Derivados de 6-tert-butil-8-fluor-2-(2-hidroximetil-3-{1-metil-5-piridin-2-il-amino-6-oxo-1,6-dihidro-piridin-3-il}-fenil)-ftalazin-1-ona como inhibidores de la tirosina-quinasa de bruton
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
NO20092415L (no) Heteromonocyklisk forbindelse og anvendelse derav
PE20142282A1 (es) Nuevos derivados de aril-quinolina
AR071694A1 (es) Procedimiento para la obtencion de arilcarboxamidas
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
PE20120911A1 (es) Derivados de prolina como inhibidores de catepsina
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
PE20120689A1 (es) Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
PE20120657A1 (es) Compuesto para el tratamiento de trastornos metabolicos

Legal Events

Date Code Title Description
FD Application declared void or lapsed